Compare · FRMM vs NVO
FRMM vs NVO
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- FRMM operates in Finance, while NVO operates in Health Care - the two are in different parts of the market.
- NVO is the larger of the two at $179.11B, about 4149.8x FRMM ($43.2M).
- NVO has been more active in the news (6 items in the past 4 weeks vs 3 for FRMM).
- NVO has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $43.2M
- $179.11B
- 1M return
- -
- +7.08%
- 1Y return
- -
- -16.66%
- Industry
- Finance: Consumer Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 3
- 6
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FRMM
- Forum Edge AI Announces $94.4 Million Definitive AI Cloud Services Compute Agreement with Fireworks
- SEC Form 8-K filed by Forum Markets Incorporated
- Forum Announces Third Quarter 2026 Earnings Release Date and Webcast Details
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Forum Markets Announces Joint Venture with Edge Node AI to Deploy Inference AI Compute Across the U.S. at Existing Powered Data Sites and Mobile Communications Towers
- Forum Markets Incorporated filed SEC Form 8-K: Leadership Update
- Forum Markets Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Sidoti Events, LLC's August Micro-Cap Virtual Conference
- Chief Executive Officer Rudisill Mcandrew covered exercise/tax liability with 98,174 shares, decreasing direct ownership by 5% to 1,786,805 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Forum Markets Incorporated
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S